Intraperitoneal Dexmedetomidine Versus Magnesium as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorAlexandria University
About this trial
Although both dexmedetomidine and magnesium sulphate have been individually evaluated as adjuvants to local anesthetics, direct comparisons between the two agents in intraperitoneal instillation during laparoscopic cholecystectomy remain limited. Understanding their relative efficacy and safety could provide valuable guidance for optimizing perioperative analgesia in these patients.
Eligibility criteria
Qualifiers
Patients aged 18-60 years
ASA physical status I-II
scheduled for elective laparoscopic cholecystectomy under general anesthesia.
Disqualifiers
Known hypersensitivity to study drugs
history of cardiac arrhythmias or conduction abnormalities
severe hepatic/renal impairment
chronic opioid or analgesic use
Trial design
Treatments tested in this trial
- Bupivacaine 100 mg + dexmedetomidine 1 µg/kg
- Bupivacaine 100 mg + magnesium sulphate 50 mg/kg
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov